Emmecell   Report issue

For profit Phase 1
Founded: North Fair Oaks CA United States (2015)

Organization Overview

First Clinical Trial
2016
NCT04191629
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Emmecell

Active Ingredients

Drugs in Phase 1 Trials (2)

Magnetic Human Corneal Endothelial Cells (4 trials)

ripasudil (Glanatec) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Corneal Edema (Phase 1)

Edema (Phase 1)

Fuchs' Endothelial Dystrophy (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 4
  • # of Trial APIs: 2